Stockreport
GILEAD AND GALAPAGOS ANNOUNCE TORTUGA PHASE 2 STUDY OF FILGOTINIB IN ANKYLOSING SPONDYLITIS ACHIEVES PRIMARY ENDPOINT
Last galapagos nv ads earnings: 4/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: glpg.com/company-overview
PDF
Foster City, Calif. and Mechelen, Belgium; September 6, 2018; 7.00 CET; Regulated information - Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the randomized, placebo-controlled Phase 2 TORTUGA study of filgotinib, an investigational, selective JAK1 inhibitor, achieved its primary efficacy endpoint in adults with moderately to severely active ankylosing spondylitis (AS). In the study, patients treated with filgotinib achieved significantly greater improvements in AS Disease Activity Score (ASDAS), the primary endpoint, at Week 12, with a mean change from baseline of -1.5 versus -0.6 for those treated with placebo (p[1] response compared to those treated with placebo (76 percent versus 40 percent, p "People with ankylosing spondylitis face serious pain and disability, and, too often, their disease does not respond adequately to existing therapies," said John McHutchison, MD, Chief Scientific Officer, Head of Research and Develop
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | GLPG | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
GLPG alerts
GLPG alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLPG alerts
High impacting Galapagos NV ADS news events
Weekly update
A roundup of the hottest topics
GLPG
NEWS
NEWS
- GALAPAGOS NV/S (NASDAQ: GLPG) was upgraded by analysts at Credit Suisse Group AG to a "buy" rating.[MarketBeat]
- GALAPAGOS NV/S (NASDAQ: GLPG) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $115.00 price target on the stock.[MarketBeat]
- The Wall Street Journal: Biotech investor G. Steven Burrill gets 30 months in prison for tax evasion, fraud [MarketWatch][MarketWatch]
- Galapagos receives Fast Track designation from FDA for GLPG1972/S201086 in osteoarthritis[GlobeNewswire]
- Transparency notification[GlobeNewswire]
- More
GLPG
SEC Filings
SEC Filings
- 11/28/18 - Form 6-K
- 11/27/18 - Form 6-K
- 11/26/18 - Form 6-K
- GLPG's page on the SEC website
- More